These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24658197)

  • 1. Early steroid withdrawal in a renal transplant cohort treated with tacrolimus, mycophenolate mofetil and basiliximab.
    Andrade-Sierra J; Rojas-Campos E; Cardona-Muñoz E; Evangelista-Carrillo LA; Puentes-Camacho A; Lugo-López O; Gómez B; Valdespino C; Cerrillos I; Medina-Pérez M; Jalomo B; Nieves JJ; Sandoval M; Ramos-Solano F; Monteón-Ramos F; Cueto-Manzano AM
    Nefrologia; 2014; 34(2):216-22. PubMed ID: 24658197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
    Martin ST; Roberts KL; Malek SK; Tullius SG; Vadivel N; De Serres S; Grafals M; Elsanjak A; Filkins BA; Chandraker A; Gabardi S
    Pharmacotherapy; 2011 Jun; 31(6):566-73. PubMed ID: 21923440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.
    Libório AB; Mendoza TR; Esmeraldo RM; Oliveira ML; Paes FJ; Silva Junior GB; Daher EF
    Int Immunopharmacol; 2011 Nov; 11(11):1832-6. PubMed ID: 21835269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
    Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
    Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
    Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
    Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab.
    Ojogho O; Sahney S; Cutler D; Baron PW; Abdelhalim FM; James S; Zuppan C; Franco E; Concepcion W
    Pediatr Transplant; 2005 Feb; 9(1):80-3. PubMed ID: 15667617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes.
    Humar A; Crotteau S; Gruessner A; Kandaswamy R; Gruessner R; Payne W; Lake J
    Clin Transplant; 2007; 21(4):526-31. PubMed ID: 17645714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
    Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
    Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
    Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective controlled protocol for three months steroid withdrawal with tacrolimus, basiliximab, and mycophenolate mofetil in renal transplant recipients.
    Oh CK; Kim SJ; Kim JH; Lee JH
    J Korean Med Sci; 2012 Apr; 27(4):337-42. PubMed ID: 22468094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early steroid withdrawal in adult kidney transplantation at a single center.
    Iwamoto H; Hama K; Konno O; Yokoyama T; Kihara Y; Jojima Y; Nakamura Y; Takeuchi H; Shimazu M
    Transplant Proc; 2012 Jan; 44(1):179-81. PubMed ID: 22310609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
    Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
    Montini G; Murer L; Ghio L; Pietrobon B; Ginevri F; Ferraresso M; Cardillo M; Scalamogna M; Perfumo F; Edefonti A; Zanon GF; Zacchello G
    Transpl Int; 2005 Jan; 18(1):36-42. PubMed ID: 15612981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steroid withdrawal or steroid avoidance in renal transplant recipients: focus on tacrolimus-based immunosuppressive regimens.
    Krämer BK; Krüger B; Mack M; Obed A; Banas B; Paczek L; Schlitt HJ
    Transplant Proc; 2005 May; 37(4):1789-91. PubMed ID: 15919467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
    Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal Study Group.
    Ahsan N; Hricik D; Matas A; Rose S; Tomlanovich S; Wilkinson A; Ewell M; McIntosh M; Stablein D; Hodge E
    Transplantation; 1999 Dec; 68(12):1865-74. PubMed ID: 10628766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.